S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NYSE:EW

Edwards Lifesciences (EW) Stock Price, News & Analysis

$87.74
+0.12 (+0.14%)
(As of 02/23/2024 ET)
Today's Range
$87.37
$88.33
50-Day Range
$72.55
$88.25
52-Week Range
$60.57
$94.87
Volume
2.80 million shs
Average Volume
4.04 million shs
Market Capitalization
$52.76 billion
P/E Ratio
38.15
Dividend Yield
N/A
Price Target
$87.38

Edwards Lifesciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
0.4% Downside
$87.38 Price Target
Short Interest
Healthy
1.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.79mentions of Edwards Lifesciences in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$14.40 M Sold Last Quarter
Proj. Earnings Growth
11.96%
From $2.76 to $3.09 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.63 out of 5 stars

Medical Sector

67th out of 939 stocks

Surgical Appliances & Supplies Industry

3rd out of 17 stocks


EW stock logo

About Edwards Lifesciences Stock (NYSE:EW)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

EW Stock Price History

EW Stock News Headlines

Can financial, healthcare, energy stocks rise as rates stay high? (EW)
Sectors including financials, healthcare, utilities and energy outperform as interest rates remain high, but some of those industries face challenges in 2024.
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Wells Fargo Reaffirms Their Buy Rating on Edwards Lifesciences (EW)
Q4 2023 Edwards Lifesciences Corp Earnings Call
See More Headlines
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/06/2024
Today
2/23/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
CUSIP
28176E10
Employees
19,800
Year Founded
1958

Price Target and Rating

Average Stock Price Target
$87.38
High Stock Price Target
$107.00
Low Stock Price Target
$57.00
Potential Upside/Downside
-0.2%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
16 Analysts

Profitability

Net Income
$1.40 billion
Pretax Margin
26.61%

Debt

Sales & Book Value

Annual Sales
$6.00 billion
Cash Flow
$2.79 per share
Book Value
$11.18 per share

Miscellaneous

Free Float
593,543,000
Market Cap
$52.67 billion
Optionable
Optionable
Beta
1.04

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Edwards Lifesciences was last updated on Tuesday, February 20, 2024 at 10:44 PM.

Pros

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

  • Edwards Lifesciences provides innovative transcatheter heart valve replacement products, offering minimally invasive solutions for heart valve replacement procedures.
  • The company offers critical care monitoring systems that provide valuable hemodynamic information to clinicians, aiding in patient care in surgical and intensive care settings.
  • Recent developments in the company's product lines, such as the PASCAL PRECISION and Cardioband transcatheter heart valve repair and replacement products, showcase a commitment to advancing treatment options for mitral and tricuspid valve diseases.
  • Edwards Lifesciences has a strong presence in the United States, Europe, Japan, and internationally, providing geographic diversification for investors.
  • Investors may find the current stock price of Edwards Lifesciences Co. attractive, considering the growth potential and market positioning of the company within the health care equipment industry.

Cons

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

  • Market competition in the health care equipment industry could impact Edwards Lifesciences' market share and pricing strategies, potentially affecting investor returns.
  • Regulatory challenges and changes in health care policies could introduce uncertainties for the company's product approvals and market access, influencing investor confidence.
  • Fluctuations in global economic conditions and healthcare spending trends may impact the demand for Edwards Lifesciences' products, affecting revenue growth and investor expectations.
  • Investors should consider the potential risks associated with currency exchange rates, as Edwards Lifesciences operates internationally, exposing the company to foreign exchange fluctuations.
  • Changes in reimbursement policies for medical procedures and devices could affect the adoption rates of Edwards Lifesciences' products, influencing the company's financial performance and investor sentiment.














EW Stock Analysis - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 7 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
View EW analyst ratings
or view top-rated stocks.

What is Edwards Lifesciences' stock price target for 2024?

16 Wall Street analysts have issued 12 month price objectives for Edwards Lifesciences' stock. Their EW share price targets range from $57.00 to $107.00. On average, they expect the company's stock price to reach $87.38 in the next twelve months. This suggests that the stock has a possible downside of 0.4%.
View analysts price targets for EW
or view top-rated stocks among Wall Street analysts.

How have EW shares performed in 2024?

Edwards Lifesciences' stock was trading at $76.25 at the beginning of 2024. Since then, EW stock has increased by 15.1% and is now trading at $87.74.
View the best growth stocks for 2024 here
.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 9,960,000 shares, a drop of 8.4% from the January 15th total of 10,870,000 shares. Based on an average trading volume of 4,540,000 shares, the short-interest ratio is presently 2.2 days. Approximately 1.7% of the shares of the company are sold short.
View Edwards Lifesciences' Short Interest
.

When is Edwards Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our EW earnings forecast
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) announced its quarterly earnings data on Tuesday, February, 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting analysts' consensus estimates of $0.64. The medical research company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.50 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 23.56% and a net margin of 23.35%. The business's revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter last year, the company earned $0.64 EPS.
Read the conference call transcript
.

When did Edwards Lifesciences' stock split?

Edwards Lifesciences shares split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were payable to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share (EPS) guidance of 0.620-0.660 for the period, compared to the consensus estimate of 0.660. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.63%), Brown Advisory Inc. (3.00%), Capital International Investors (1.49%), Norges Bank (1.40%), Fisher Asset Management LLC (1.18%) and Sands Capital Management LLC (1.01%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends
.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Edwards Lifesciences have any subsidiaries?
The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More
This page (NYSE:EW) was last updated on 2/23/2024 by MarketBeat.com Staff